NO963497L - Fibrin-spesifikt antistoff for anvendelse som et antitrombotisk middel - Google Patents

Fibrin-spesifikt antistoff for anvendelse som et antitrombotisk middel

Info

Publication number
NO963497L
NO963497L NO963497A NO963497A NO963497L NO 963497 L NO963497 L NO 963497L NO 963497 A NO963497 A NO 963497A NO 963497 A NO963497 A NO 963497A NO 963497 L NO963497 L NO 963497L
Authority
NO
Norway
Prior art keywords
fibrin
specific antibody
antithrombotic agent
methods
antithrombotic
Prior art date
Application number
NO963497A
Other languages
English (en)
Norwegian (no)
Other versions
NO963497D0 (no
Inventor
Paul Edward Gargan
Original Assignee
American Biogenetic Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Biogenetic Sciences filed Critical American Biogenetic Sciences
Publication of NO963497D0 publication Critical patent/NO963497D0/no
Publication of NO963497L publication Critical patent/NO963497L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO963497A 1994-02-24 1996-08-22 Fibrin-spesifikt antistoff for anvendelse som et antitrombotisk middel NO963497L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/204,015 US5487892A (en) 1994-02-24 1994-02-24 Method for treating thrombotic disease using a fibrin specific monoclonal antibody
PCT/US1995/001825 WO1995022986A1 (en) 1994-02-24 1995-02-21 Fibrin-specific antibody for use as an antithrombotic agent

Publications (2)

Publication Number Publication Date
NO963497D0 NO963497D0 (no) 1996-08-22
NO963497L true NO963497L (no) 1996-10-16

Family

ID=22756260

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963497A NO963497L (no) 1994-02-24 1996-08-22 Fibrin-spesifikt antistoff for anvendelse som et antitrombotisk middel

Country Status (26)

Country Link
US (1) US5487892A (lt)
EP (1) EP0749320A4 (lt)
JP (1) JPH09509429A (lt)
KR (1) KR970701063A (lt)
CN (1) CN1146157A (lt)
AU (1) AU708897B2 (lt)
BG (1) BG62476B1 (lt)
BR (1) BR9506949A (lt)
CA (1) CA2183953A1 (lt)
CZ (1) CZ246496A3 (lt)
FI (1) FI963288A7 (lt)
GE (1) GEP20002257B (lt)
HU (1) HUT76536A (lt)
LT (1) LT4192B (lt)
LV (1) LV11784B (lt)
MD (1) MD1521G2 (lt)
MX (1) MX9603602A (lt)
NO (1) NO963497L (lt)
NZ (1) NZ281481A (lt)
PL (1) PL316005A1 (lt)
RU (1) RU2152801C2 (lt)
SG (1) SG53279A1 (lt)
SK (1) SK108496A3 (lt)
TJ (1) TJ301B (lt)
UA (1) UA41984C2 (lt)
WO (1) WO1995022986A1 (lt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5453359A (en) * 1988-06-13 1995-09-26 American Biogenetic Sciences, Inc. Immunoassay and kit for in vitro detection of soluble DesAABB fibrin polymers
US5817768A (en) * 1995-06-07 1998-10-06 The New York Blood Center, Inc. Monospecific antibodies against a subunit of fibrinogen
US6727102B1 (en) 1997-06-20 2004-04-27 Leuven Research & Development Vzw Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins
US6309888B1 (en) * 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
IL134828A0 (en) * 2000-03-01 2001-05-20 Eship 4U Com Inc System for delivery and receipt of dispatches especially useful for e-commerce
US8658773B2 (en) 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
US20050181451A1 (en) * 2004-02-12 2005-08-18 Bates Harold M. Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
JP4088328B2 (ja) * 2004-12-28 2008-05-21 第一化学薬品株式会社 抗ヒト可溶性フィブリンモノクローナル抗体及び当該抗体を用いる免疫学的測定方法
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
CA3177936A1 (en) 2012-12-13 2014-06-19 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
CN110563258A (zh) * 2019-09-06 2019-12-13 广东石油化工学院 一种猪场废水厌氧产氢与达标排放处理方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU572125B2 (en) * 1983-03-17 1988-05-05 Mabco Limited Monoclonal antibodies with specificity for crosslinked fibrin and their diagnotic uses
US4722903A (en) * 1983-11-14 1988-02-02 New York Blood Center, Inc. Monoclonal antibodies specific to in vivo fragments derived from human fibrinogen, human fiberin I or human fibrin II
GB8605316D0 (en) * 1986-03-04 1986-04-09 Royal Free Hosp School Med Immunosuppression
JP2635343B2 (ja) * 1986-04-14 1997-07-30 ザ・ジェネラル・ホスピタル・コーポレーション ヘテロ二官能性抗体および利用方法
US4916070A (en) * 1986-04-14 1990-04-10 The General Hospital Corporation Fibrin-specific antibodies and method of screening for the antibodies
WO1988001514A1 (en) * 1986-08-25 1988-03-10 American Biogenetic Sciences, Inc. Monoclonal antibodies to fibrin
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3701812A1 (de) * 1987-01-22 1988-08-04 Max Planck Gesellschaft Fibrinspezifischer antikoerper, verfahren zur seiner herstellung und seine verwendung
US5120834A (en) * 1988-06-13 1992-06-09 American Biogenetic Sciences, Inc. Fibrin-specific monoclonal antibody
US5223410A (en) * 1988-06-13 1993-06-29 American Biogenetic Sciences, Inc. Method for production of antibodies utilizing an antigen-free animal
SG50681A1 (en) * 1988-06-13 1998-07-20 American Biogenetic Sciences Method for the production of monoclonal antibodies utilizing a germfree animal
US5091512A (en) * 1988-06-13 1992-02-25 American Biogenetic Sciences, Inc. Fibrinogen-specific monoclonal antibody
US5206140A (en) 1988-06-24 1993-04-27 Research Corporation Technologies, Inc. Assay for soluble crosslinked fibrin polymers
CA2052283A1 (en) * 1990-09-27 1992-03-28 Edgar Haber Recombinant hybrid immunoglobulin molecules and method of use

Also Published As

Publication number Publication date
FI963288A0 (fi) 1996-08-23
HU9602337D0 (en) 1996-10-28
LV11784B (en) 1997-12-20
LT4192B (en) 1997-07-25
CN1146157A (zh) 1997-03-26
KR970701063A (ko) 1997-03-17
MX9603602A (es) 1997-05-31
EP0749320A4 (en) 1997-06-18
BG100863A (en) 1997-08-29
HUT76536A (en) 1997-09-29
CZ246496A3 (en) 1997-04-16
MD960334A (en) 1997-09-30
MD1521F2 (en) 2000-08-31
MD1521G2 (ro) 2001-03-31
PL316005A1 (en) 1996-12-23
JPH09509429A (ja) 1997-09-22
FI963288L (fi) 1996-08-23
RU2152801C2 (ru) 2000-07-20
LV11784A (lv) 1997-06-20
WO1995022986A1 (en) 1995-08-31
NZ281481A (en) 1998-07-28
NO963497D0 (no) 1996-08-22
SK108496A3 (en) 1997-10-08
UA41984C2 (uk) 2001-10-15
BR9506949A (pt) 1997-09-23
AU1843495A (en) 1995-09-11
AU708897B2 (en) 1999-08-12
US5487892A (en) 1996-01-30
TJ301B (en) 2001-08-06
SG53279A1 (en) 1998-09-28
FI963288A7 (fi) 1996-08-23
EP0749320A1 (en) 1996-12-27
LT96140A (en) 1997-03-25
BG62476B1 (bg) 1999-12-30
GEP20002257B (en) 2000-10-25
CA2183953A1 (en) 1995-08-31

Similar Documents

Publication Publication Date Title
YU48666B (sh) Mometason furoat monohidrat i postupak za njegovo dobijanje
ID29393A (id) Komposisi pengobatan kanker dan metoda penggunaan minyak-minyak esensil tanaman alamiah
FI924553A0 (fi) Tiofensulfonamider anvaendbara som kolanhydrasinhibitorer
MX9700082A (es) Composicion que consiste de morfina, polipirrolidona y oxido de polialquileno.
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
DK0725790T3 (da) Substituerede tetra- og pentapeptidinhibitorer af proteinfarnesyltransferase
DK0833839T3 (da) Heterocykliske peptidylforbindelser, der er nyttige til behandling af thrombinrelaterede sygdomme
MY141384A (en) Prevention of loss and restoration of bone mass by certain prostaglandin agonists
TR199800759T2 (xx) Protein Kinaz C �nhibit�r�.
NO974572D0 (no) Cyklodextrin-forbindelser, fremgangsmåter for fremstilling og anvendelse derav
MX9709146A (es) Compuestos novedosos, preparacion y uso de los mismos.
NO963497L (no) Fibrin-spesifikt antistoff for anvendelse som et antitrombotisk middel
DE69116550D1 (de) Steroid-sulfatase-inhibitoren
NO975557L (no) Immortalisering og dissimortalisering av celler
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
NO944764D0 (no) Inklusjonskomplekser i vandige opplösninger av benzotiofenforbindelser med vannopplöselige cyklodekstriner og farmasöytiske formuleringer og fremgangsmåter
GR1000965B (el) Παραγωγα της σακχαρινης χρησιμοποιουμενα ως ανασταλτικα των πρωτεολυτικων ενζυμων και μεθοδος παρασκευης αυτων
ATE38036T1 (de) Benzothiophenderivate als bronchodilatoren.
NO980178D0 (no) Cyklo-oksygenase-inhibitor og amidin-derivatsalter, fremgangsmåte for fremstilling derav, anvendelse derav som legemidler, og farmasöytiske blandinger inneholdende slike derivater
ATE139226T1 (de) Aminosulfonylharnstoff-acat-inhibitoren
AU1023497A (en) Tissue factor - kunitz domain fusion proteins as factor viia inhibitors
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
IL139144A0 (en) Mycobacterial inhibitors
GEP20084346B (en) Protein kinase c inhibitors
WO1996031119A3 (de) Organische peroxoverbindungen enthaltendes mittel zur instrumentendesinfektion

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application